About | PulmOne

Scott Yokobosky

Prior to joining PulmOne, Scott was a Regional Manager in rare and orphan diseases at Mallinckrodt Neurology, and Director of Managed Care covering United Health Care at Schering Oncology. Previously, he was the National Sales Director of Rheumatology at Horizon Pharma. Scott has held several sales leadership roles in Oncology, Rheumatology, Orthopedic Medical Devices and Pulmonology at companies including Sanofi Oncology and Praecis Biotech.

Michael Mesnik

Michael Mesnik brings 10 years of experience marketing pulmonary function and cardiopulmonary medical devices. Prior to joining PulmOne, Michael held various roles from Director of Marketing to Senior Product Manager to Key Account Manager at CareFusion; spent 8 years operating a clinical exercise testing lab; and managing a cardiac stress testing facility. Michael holds a Master’s degree in Exercise Physiology from California State University Northridge. In his limited spare time, he is an avid reader, golfer, and fly fisherman.

Hudi Zack

Hudi Zack brings to PulmOne over 30 years of experience in leading business organizations, R&D, and project teams at global corporations as well as start-ups. Most recently, Hudi served as the COO of Cytegic, a cybersecurity start-up.

Previously, he founded CorrSight – a SaaS provider in the online financial brokerage arena. In the past, Hudi has held senior management positions at Verint (NASDAQ:VRNT), Amdocs (NYSE:DOX), and Metalink (NASDAQ:MTLK).

Hudi holds a master’s degree in Electrical Engineering from Tel-Aviv University (Summa Cum Laude) and a bachelor’s degree in Mathematics and Physics from the Hebrew University in Jerusalem (Cum Laude, as a member of Talpiot program).

Amit Morag

Amit Morag has 15 years of experience in the high technology industry. Prior to joining PulmOne, Amit served in various Operations, Engineering, Service and Product leadership roles, mainly in the medical devices and telecommunications industries, including General Electric Healthcare. Amit holds a B.Sc in Engineering and MBA, both from Tel-Aviv University.

Download MiniBox+ Brochure

USA Brochure

International Brochure

Download our White Paper:

Total Lung Capacity with the MiniBox: Clinical Results in Obstructed, Restrictive, and Healthy Adults

Dr. Marc Rothenberg

Dr. Rothenberg is the Director of the Division of Allergy and Immunology at Cincinnati Children’s Hospital Medical Center (Cincinnati Children’s), a tenured Professor of Pediatrics at Cincinnati Children’s and the University of Cincinnati College of Medicine (UCCOM), the Founder and Director of the Cincinnati Center for Eosinophilic Disorders (CCED), and the Founder and Director of the NIH-sponsored, national Consortium of Eosinophilic Disease Researchers (CEGIR).

He graduated summa cum laude with Highest Honors in Chemistry and Biochemistry from Brandeis University. At Harvard Medical School (HMS), he completed the combined MD/PhD program. After completing a residency in pediatrics at Children’s Hospital in Boston, Dr. Rothenberg did a combined fellowship in Allergy/Immunology and Hematology at Children’s Hospital and a post-doctorate training in Boston. He came to the UCCOM and Cincinnati Children’s in 1996 and has helped build a top program in pediatric research; his division is a leader in pediatric allergy and immunology.

His research is focused on molecular analysis of allergic inflammation. Dr. Rothenberg’s awards include the 2007 E. Mead Johnson Award from the Society of Pediatric Research, an NIH MERIT Award in 2010 and he is a member of the Hewlett-Woodmere Alumni Hall of Fame. He is an elected member of the ASCI, AAP, AAAS and SPR. His publications number over 325. He has served on various review panels for journals and grant agencies including the NIH, Burroughs Trust, the MRC of the UK and the ISF of Israel. He is an Associate Editor of the Journal of Allergy and Clinical Immunology, and Mucosal Immunology, and co-Section Head of the Allergy and Hypersensitivity Section of Faculty 1000. He is the Inventor of over 20 patents, issued or pending. He has served as a key Consultant to a number of Start-Up Companies that have subsequently become public entities. He has served a four-year term on the Advisory Council of the NIAID. His research has been supported by numerous sources including the NIH, Human Frontier Science Program Organization, the Burroughs Wellcome Fund, the Dana Foundation, the US Department of Defense, US-Israel Binational Fund, and PCORI. He has trained a myriad of clinical and research investigators in his own laboratory and also as Program Director and/or Co-Principal Investigator of several NIH training grants including the NIH CTSA KL2, NICHD CHRCDA K12, and NIAID T32.

Eran Sasson

Eran Sasson brings to PulmOne 14 years of experience in the international sales. Prior to PulmOne Eran served as VP intentional sales in EndyMed for more than 6 years where he applied his expertise in international sales and significantly increased sales performance. Prior to EndyMed he served as Director of Sales Europe in Syneron Medical and Director of Sales west Europe in Radiancy.

Dror Paz

Dror Paz joined PulmOne as VP of Sales & Business Development in May 2016. He has an extensive background and experience in the Global Healthcare Industry. Dror has been involved with medical finance, marketing, business development and sales management in medical imaging, healthcare, and medical training and simulation companies for almost 2 decades.

Prior to joining the Company, Dror spent 9 years and was the VP of North American Sales at Simbionix USA Corporation/3D Systems where he was a major contributor in transforming Simbionix to become the world’s leader company in MIS training and simulation solutions. Simbionix was acquired by 3D Systems on August 2014. Prior to Simbionix Dror spent 8 years with GE Healthcare where he was responsible for MRI and the entire X-Ray modalities sales in Israel.

Dror earned his B.Sc in Finance with honors from the University of Illinois at Chicago (UIC).

Avi Lazar

Avi Lazar founded PulmOne Advanced Medical Devices Ltd. in March 2006, and has been serving as CEO since its inception. Prior to PulmOne, Avi served as Chief Executive Officer and Chief Financial Officer in several Israeli technology companies, where he was instrumental in raising over $50 million from prominent financial and strategic investors, such as Cisco Systems, Lehman Brothers, Philips, JP Morgan Partners, Texas Instruments, ABN Amro and others. Avi has also served on a number of Boards. Before these corporate activities, Avi held senior positions with international accounting firm Ernst & Young, where he was responsible for several successful initial public offerings in NASDAQ and TASE.

Prof. Robert Brown

Prof. Robert Brown is Director of Pulmonary Function Laboratory and the Medical Director of the Respiratory Acute Care Unit at the Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. He joined PulmOne’s Scientific Advisory Board in 2010.

Prof. Brown served on the editorial boards of Medicine International, the Journal of the American Paraplegia Society (section editor), the Journal of Spinal Cord Injury Medicine (section editor), the Journal of Spinal Cord Injury Medicine (associate editor) and the Archives of Physical Medicine and Rehabilitation.

Prof. Jeffrey J. Fredberg

Prof. Jeffrey J. Fredberg is a professor of BioEngineering and Physiology at the Harvard School of Public Health. He joined PulmOne’s Scientific Advisory Board in 2010.

Prof. Fredberg served on the editorial boards of the Journal of Applied Physiology, Respiratory Research, American Journal of Physiology and Mechanics & Chemistry of Biosystems.

Prof. Fredberg’s many past and present roles include serving on the ATS board of directors, NIH Respiratory Sciences Study Section Boundary Team, the NSF/NIH Interagency Panel on Bridging the Life and Physical Sciences, the NHLBI Working Group on Nanotechnology in Heart, Lung, Blood, and Sleep Medicine, and the Heart, Lung, and Blood Program Project Review Committee (study section HLBP) of the NHLBI.